



(19) REPUBLIKA HRVATSKA  
DRŽAVNI ZAVOD ZA  
INTELEKTUALNO VLASNIŠTVO



(10) Identifikator  
dokumenta:

HR P20120763 T1

HR P20120763 T1

(12) **PRIJEVOD PATENTNIH ZAHTJEVA  
EUROPSKOG PATENTA**

(51) MKP:

**A61K 31/351** (2006.01)  
**A61P 3/00** (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 31.10.2012.

(21) Broj predmeta: P20120763T

(22) Datum podnošenja zahtjeva u HR: 26.09.2012.

(86) Broj međunarodne prijave: PCT/EP2008000029  
Datum podnošenja međunarodne prijave: 04.01.2008.

(96) Broj europske prijave patenta: EP 08700981.7  
Datum podnošenja europske prijave patenta: 04.01.2008.

(87) Broj međunarodne objave: WO 2008086949  
Datum međunarodne objave: 24.07.2008.

(97) Broj objave europske prijave patenta: EP 2120923 A1  
Datum objave europske prijave patenta: 25.11.2009.

(97) Broj objave europskog patenta: EP 2120923 B1  
Datum objave europskog patenta: 18.07.2012.

(31) Broj prve prijave: 102007002260

(32) Datum podnošenja prve prijave:

16.01.2007.

(33) Država ili organizacija podnošenja prve prijave: DE

(73) Nositelj patenta:

**SANOFI, 54 rue La Boétie, 75008 Paris, FR**

(72) Izumitelji:

**Harm Brummerhop, c/o Sanofi-Aventis Deutschland GmbH, 65926  
Frankfurt am Main, DE**

**Siegfried Stengel, c/o Sanofi-Aventis Deutschland GmbH, 65926  
Frankfurt am Main, DE**

**Hubert Heuer, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt  
am Main, DE**

**Susanne Kilp, Kirchstrasse 12, 55452 Hergendorf, DE**

**Andreas Herling, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt  
am Main, DE**

**Thomas Klabunde, c/o Sanofi-Aventis Deutschland GmbH, 65926  
Frankfurt am Main, DE**

**Dieter Kadereit, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt  
am Main, DE**

**Matthias Urmann, c/o Sanofi-Aventis Deutschland GmbH, 65926  
Frankfurt am Main, DE**

(74) Zastupnik:

Mraste & Partneri odvjetničko društvo, 10000 Zagreb, HR


(54) Naziv izuma:

**UPOTREBA SUPSTITUIRANIH DERIVATA PIRANONSKE KISELINE U LIJEČENJU  
METABOLIČKOG SINDROMA**

HR P20120763 T1

## PATENTNI ZAHTJEVI

## 5 1. Upotreba spoja formule I,



u kojoj

10 R1 je H, F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkil, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, CONH<sub>2</sub>, (C<sub>1</sub>-C<sub>20</sub>)-alkil, (C<sub>3</sub>-C<sub>20</sub>)-cikloalkil, (C<sub>2</sub>-C<sub>20</sub>)-alkenil, (C<sub>2</sub>-C<sub>20</sub>)-alkinil, aril, heterocikl, gdje u (C<sub>1</sub>-C<sub>20</sub>)-alkilnim i (C<sub>2</sub>-C<sub>20</sub>)-alkenilnim radikalima jedna ili više pojedinačnih skupina -CH<sub>2</sub>- ili -CH- može biti zamijenjeno s -O-, te gdje alkilni, cikloalkilni, alkenilni, alkinilni, aril- i heterociklilni radikali mogu biti supstituirani s jednim ili više

15 F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, N<sub>3</sub>, CN, =O, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkila, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkil]<sub>2</sub>, cikloalkila, (C<sub>1</sub>-C<sub>10</sub>)-alkila, (C<sub>2</sub>-C<sub>6</sub>)-alkenila, (C<sub>2</sub>-C<sub>6</sub>)-alkinila, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-arila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-heterociklila;

20 PO<sub>3</sub>H<sub>2</sub>, P(O)(Oalkil)<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkilen-P(O)(Oalkil)<sub>2</sub>, O-P(O)(OH)<sub>2</sub>, O-P(O)(Oalkil)<sub>2</sub>, SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkil, S-(CH<sub>2</sub>)<sub>n</sub>-aril, S-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO-(CH<sub>2</sub>)<sub>n</sub>-aril, SO-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-NH(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-NH(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-N((CH<sub>2</sub>)<sub>n</sub>-aril)<sub>2</sub>, SO<sub>2</sub>-N((CH<sub>2</sub>)<sub>n</sub>-heterociklil)<sub>2</sub>, gdje n = 0-6, a arilni radikal ili heterociklički radikal mogu biti supstituirani s dva F, Cl, Br, OH, CF<sub>3</sub>, SF<sub>5</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>; C(NH)(NH<sub>2</sub>), NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acil, NH-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-CO-aril, NH-CO-heterociklil, NH-COO-aril, NH-COO-heterociklil, NH-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-CO-NH-aril, NH-CO-NH-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N(aril)<sub>2</sub>, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N(heterociklil)<sub>2</sub>, N(aril)-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-CO-aril, N(heterociklil)-CO-aril, N(aril)-COO-aril, N(heterociklil)-COO-aril, N(aril)-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-CO-NH-aril, N(heterociklil)-CO-NH-aril, N(aril)-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N(heterociklil)-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N(aril)-CO-N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-aril, N(heterociklil)-CO-N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-aril, N(aril)-CO-N(aril)<sub>2</sub>, N(heterociklil)-CON(aril)<sub>2</sub>, aril, O-(CH<sub>2</sub>)<sub>n</sub>-aril, O-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, gdje n = 0-6, te gdje arilni ili heterociklilni radikal mogu biti supstituirani s jednim do tri F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkila, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>;

40 R2 je H, F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkil, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, CONH<sub>2</sub>, (C<sub>1</sub>-C<sub>20</sub>)-alkil, (C<sub>3</sub>-C<sub>20</sub>)-cikloalkil, (C<sub>2</sub>-C<sub>20</sub>)-alkenil, (C<sub>2</sub>-C<sub>20</sub>)-alkinil, aril, heterocikl, gdje u (C<sub>1</sub>-C<sub>20</sub>)-alkilnim i (C<sub>2</sub>-C<sub>20</sub>)-alkenilnim radikalima jedna ili više pojedinačnih skupina -CH<sub>2</sub>- ili -CH- može biti zamijenjeno s -O-, te gdje alkilni, cikloalkilni, alkenilni, alkinilni, arilni i heterociklički radikali mogu biti supstituirani s jednim ili više

45 F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, N<sub>3</sub>, CN, =O, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkila, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkil]<sub>2</sub>, cikloalkila, (C<sub>1</sub>-C<sub>10</sub>)-alkila, (C<sub>2</sub>-C<sub>6</sub>)-alkenila, (C<sub>2</sub>-C<sub>6</sub>)-alkinila, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-arila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-heterociklila;

50 PO<sub>3</sub>H<sub>2</sub>, P(O)(Oalkil)<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkilen-P(O)(Oalkil)<sub>2</sub>, O-P(O)(OH)<sub>2</sub>, O-P(O)(Oalkil)<sub>2</sub>, SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkil, S-(CH<sub>2</sub>)<sub>n</sub>-aril, S-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO-(CH<sub>2</sub>)<sub>n</sub>-aril, SO-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-NH(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-NH(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-N((CH<sub>2</sub>)<sub>n</sub>-aril)<sub>2</sub>, SO<sub>2</sub>-N((CH<sub>2</sub>)<sub>n</sub>-heterociklil)<sub>2</sub>, gdje n = 0-6, a arilni radikal ili heterociklički radikal mogu biti supstituirani s dva F, Cl, Br, OH, CF<sub>3</sub>, SF<sub>5</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>; C(NH)(NH<sub>2</sub>), NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acil, NH-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-CO-aril, NH-CO-

heterociklil, NH-COO-aril, NH-COO-heterociklil, NH-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-CO-NH-aril, NH-CO-NH-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N(aril)<sub>2</sub>, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N(heterociklil)<sub>2</sub>, N(aril)-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-CO-aril, N(heterociklil)-CO-aril, N(aril)-COO-aril, N(heterociklil)-COO-aril, N(aril)-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-CO-NH-aril, N(heterociklil)-CO-NH-aril, N(aril)-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N(heterociklil)-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N(aril)-CO-N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-aril, N(heterociklil)-CO-N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-aril, N(aril)-CO-N(aril)<sub>2</sub>, N(heterociklil)-CON(aril)<sub>2</sub>, aril, O-(CH<sub>2</sub>)<sub>n</sub>-aril, O-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, gdje n = 0-6, te gdje arilni ili heterociklilni radikal mogu biti supstituirani s jednim do tri F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkila, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>;

ili R1 i R2 zajedno tvore 3- do 8-eročlani arilni, cikloalkilni ili heterociklilni prsten, gdje arilni, cikloalkilni ili heterociklilni prsten mogu biti supstituirani s F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkilom, (C<sub>1</sub>-C<sub>6</sub>)-alkilom, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkilom, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkilom, CONH<sub>2</sub>, te gdje arilni, cikloalkilni ili heterociklilni prsten mogu biti kondenzirani s dodatnim arilnim, cikloalkilnim ili heterociklilnim prstenom;

i njegovih fiziološki prihvatljivih soli, **naznačena time** što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje metaboličkog sindroma.

2. Upotreba spoja formule I u skladu s patentnim zahtjevom 1, u kojoj

R1 je H, OH, COOH, (C<sub>1</sub>-C<sub>8</sub>)-alkil, (C<sub>2</sub>-C<sub>8</sub>)-alkenil, aril, gdje u (C<sub>1</sub>-C<sub>8</sub>)-alkilnim i (C<sub>2</sub>-C<sub>8</sub>)-alkenilnim radikalima jedna ili više pojedinačnih skupina -CH<sub>2</sub>- ili -CH- može biti zamijenjeno s -O-, te gdje alkilni, alkenilni i arilni radikali mogu biti supstituirani s jednim ili više

F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, N<sub>3</sub>, CN, =O, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkila, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkil]<sub>2</sub>, cikloalkila, (C<sub>1</sub>-C<sub>10</sub>)-alkila, (C<sub>2</sub>-C<sub>6</sub>)-alkenila, (C<sub>2</sub>-C<sub>6</sub>)-alkinila, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-arila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-heterociklila;

PO<sub>3</sub>H<sub>2</sub>, P(O)(Oalkil)<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkilen-P(O)(Oalkil)<sub>2</sub>, O-P(O)(OH)<sub>2</sub>, O-P(O)(Oalkil)<sub>2</sub>, SO<sub>3</sub>H, SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkil, S-(CH<sub>2</sub>)<sub>n</sub>-aril, S-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO-(CH<sub>2</sub>)<sub>n</sub>-aril, SO-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkil, SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-NH(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-NH(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)(CH<sub>2</sub>)<sub>n</sub>-aril, SO<sub>2</sub>-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)(CH<sub>2</sub>)<sub>n</sub>-heterociklil, SO<sub>2</sub>-N((CH<sub>2</sub>)<sub>n</sub>-aril)<sub>2</sub>, SO<sub>2</sub>-N((CH<sub>2</sub>)<sub>n</sub>-heterociklil)<sub>2</sub>, gdje n = 0-6, a arilni radikal ili heterociklički radikal mogu biti supstituirani s do dva F, Cl, Br, OH, CF<sub>3</sub>, SF<sub>5</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>;


C(NH)(NH<sub>2</sub>), NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acil, NH-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-CO-aril, NH-CO-heterociklil, NH-COO-aril, NH-COO-heterociklil, NH-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, NH-CO-NH-aril, NH-CO-NH-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-COO-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-NH-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)-aril, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)-heterociklil, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N(aril)<sub>2</sub>, N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-CO-N(heterociklil)<sub>2</sub>, N(aril)-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-CO-aril, N(heterociklil)-CO-aril, N(aril)-COO-aril, N(heterociklil)-COO-aril, N(aril)-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(heterociklil)-CO-NH-(C<sub>1</sub>-C<sub>6</sub>)-alkil, N(aril)-CO-NH-aril, N(heterociklil)-CO-NH-aril, N(aril)-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N(heterociklil)-CO-N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, N(aril)-CO-N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-aril, N(heterociklil)-CO-N[(C<sub>1</sub>-C<sub>6</sub>)-alkil]-aril, N(aril)-CO-N(aril)<sub>2</sub>, N(heterociklil)-CON(aril)<sub>2</sub>, aril, O-(CH<sub>2</sub>)<sub>n</sub>-aril, O-(CH<sub>2</sub>)<sub>n</sub>-heterociklil, gdje n = 0-6, te gdje arilni ili heterociklilni radikal mogu biti supstituirani s jednim do tri F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkila, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>;

R2 je H, OH, COOH, (C<sub>1</sub>-C<sub>8</sub>)-alkil, (C<sub>3</sub>-C<sub>8</sub>)-cikloalkil, (C<sub>2</sub>-C<sub>8</sub>)-alkenil, gdje u (C<sub>1</sub>-C<sub>8</sub>)-alkilnim i (C<sub>2</sub>-C<sub>8</sub>)-alkenilnim radikalima jedna ili više pojedinačnih skupina -CH<sub>2</sub>- ili -CH- može biti zamijenjeno s -O-, te gdje alkil, cikloalkilni i alkenilni radikali mogu biti supstituirani s jednim ili više

F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, N<sub>3</sub>, CN, =O, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkila, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkil]<sub>2</sub>, cikloalkila, (C<sub>1</sub>-C<sub>10</sub>)-alkila, (C<sub>2</sub>-C<sub>6</sub>)-alkenila, (C<sub>2</sub>-C<sub>6</sub>)-alkinila, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-arila, O-CO-(C<sub>1</sub>-C<sub>6</sub>)-heterociklila;



8. Upotreba spoja formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i njegovih fiziološki prihvatljivih soli, **naznačena time** što je navedeni spoj namijenjen proizvodnji medikamenta za smanjivanje razine triglicerida u plazmi.
9. Upotreba spoja formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i njegovih fiziološki prihvatljivih soli, **naznačena time** što je navedeni spoj namijenjen proizvodnji medikamenta za profilaksu dijabetesa tip 2.
10. Upotreba spoja formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i njegovih fiziološki prihvatljivih soli, **naznačena time** što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje dijabetične dislipidemije.
11. Upotreba spoja formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i njegovih fiziološki prihvatljivih soli, **naznačena time** što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje of obesity.
12. Upotreba spoja formule I u skladu s bilo kojim od patentnih zahtjeva 1-4, u kojoj su R1 i R2 vodici, **naznačena time** što je navedeni spoj u obliku medikamenta.
13. Spoj formule I



I

**naznačen time** što

- 15 R1 je (C<sub>1</sub>-C<sub>8</sub>)-alkil ili (C<sub>2</sub>-C<sub>4</sub>)-alkenil, gdje alkilni i alkenilni radikali mogu biti supstituirani s jednim ili više F;

R2 je H;

i njegove fiziološki prihvatljive soli.

- 20 14. Spoj formule I u skladu s patentnim zahtjevom 13, **naznačen time** što R1 je (C<sub>2</sub>-C<sub>8</sub>)-alkil, gdje alkilni radikal može biti supstituiran s jednim ili više F;

R2 je H;

i njegove fiziološki prihvatljive soli.

- 25 15. Upotreba spoja formule I u skladu s patentnim zahtjevom 1, u kojoj R1 je H, OH, COOH, (C<sub>1</sub>-C<sub>8</sub>)-alkil, (C<sub>2</sub>-C<sub>8</sub>)-alkenil, aril, gdje u (C<sub>1</sub>-C<sub>8</sub>)-alkilnim i (C<sub>2</sub>-C<sub>8</sub>)-alkenilnim radikalima jedna ili više pojedinačnih skupina -CH<sub>2</sub>- ili -CH- može biti zamijenjeno s -O-, te gdje alkilni, alkenilni i arilni radikali mogu biti supstituirani s jednim ili više

30 F, =O, arila, gdje arilni radikal može biti supstituiran s jednim do tri F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkila, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>;

35 R2 je H, (C<sub>1</sub>-C<sub>8</sub>)-alkil, (C<sub>2</sub>-C<sub>8</sub>)-alkenil;

i njegovih fiziološki prihvatljivih soli, **naznačena time** što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje metaboličkog sindroma.

- 40 16. Upotreba spoja formule I u skladu s patentnim zahtjevom 1, u kojoj R1 je H, OH, (C<sub>1</sub>-C<sub>8</sub>)-alkil, (C<sub>2</sub>-C<sub>4</sub>)-alkenil, gdje u (C<sub>1</sub>-C<sub>8</sub>)-alkilnim i (C<sub>2</sub>-C<sub>4</sub>)-alkenilnim radikalima jedna ili više pojedinačnih skupina -CH<sub>2</sub>- ili -CH- može biti zamijenjeno s -O-, te gdje alkilni i alkenilni radikali mogu biti supstituirani s jednim ili više

45 F, =O, arila, gdje arilni radikal može biti supstituiran s jednim do tri F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkila, (C<sub>1</sub>-C<sub>6</sub>)-alkila, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkila, N((C<sub>1</sub>-C<sub>6</sub>)-alkil)<sub>2</sub>, SF<sub>5</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkila, CONH<sub>2</sub>;

R2 je H, (C<sub>1</sub>-C<sub>8</sub>)-alkil, (C<sub>2</sub>-C<sub>4</sub>)-alkenil;

- 50 i njegovih fiziološki prihvatljivih soli, **naznačena time** što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje metaboličkog sindroma.